SARS-CoV-2 Seroprevalence Following a Large-Scale Vaccination Campaign in Portugal: Results of the National Serological Survey, September - November 2021
Irina Kislaya(German Center for Infection Research), Carla Manita(National Institute of Health Dr. Ricardo Jorge), Paulo Gonçalves(National Institute of Health Dr. Ricardo Jorge), Verónica Gomez(National Institute of Health Dr. Ricardo Jorge), João Almeida Santos(National Institute of Health Dr. Ricardo Jorge), Sara Ramalhete(National Institute of Health Dr. Ricardo Jorge), Ana Paula Rodrigues(Microsoft (Brazil)), Rita de Sousa(Instituto Nacional de Saúde), Aryse Melo(National Institute of Health Dr. Ricardo Jorge), Marta Barreto(Administração Regional de Saúde de Lisboa e Vale do Tejo), Sofia Soeiro(National Institute of Health Dr. Ricardo Jorge), Camila Henriques(National Institute of Health Dr. Ricardo Jorge), Vânia Gaio(National Institute of Health Dr. Ricardo Jorge), Ana Rita Torres(National Institute of Health Dr. Ricardo Jorge), Raquel Guiomar
Cited by 5
Related Papers
Estimates of Pandemic Influenza Vaccine Effectiveness in Europe, 2009–2010: Results of Influenza Monitoring Vaccine Effectiveness in Europe (I-MOVE) Multicentre Case-Control Study
|PLoS Medicine|2011|303
Excess all-cause mortality during the COVID-19 pandemic in Europe – preliminary pooled estimates from the EuroMOMO network, March to April 2020
|Eurosurveillance|2020|238
Low and decreasing vaccine effectiveness against influenza A(H3) in 2011/12 among vaccination target groups in Europe: results from the I-MOVE multicentre case–control study
|Eurosurveillance|2013|198